At a glance
ClinicalIndex Comparison RecordN/ACompleted· 7 enrolled
Drug / intervention
QS21 +4 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Pilot Study of Immunization of High Risk Breast Cancer Patients With a Sialyl Lewisª -Keyhole Limpet Hemocyanin Conjugate Plus the Immunological Adjuvant QS-21
In Brief
A clinical study evaluating QS21, sialyl Lewisª-keyhole limpet hemocyanin conjugate vaccine, and 3 other interventions for Breast Cancer. Completed, enrolled 7 participants across 1 site.
Detailed Summary
RATIONALE: Vaccines may help the body build an effective immune response to kill tumor cells. Giving vaccine therapy together with QS21 may cause a stronger immune response and kill more tumor cells. PURPOSE: This clinical trial is studying the side effects and how well giving vaccine therapy together with QS21 works in treating patients with metastatic breast cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)
Timeline
N/ACompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMar 2007
First PostedMay 2007
Primary CompletionJan 2020
TodayJul 2026
First PostedMay 7, 2007
Enrollment StartMar 20, 2007
Primary CompletionJan 24, 2020
TodayJul 2, 2026
Enrollment to primary: 12.8 yearsPosted 19.2 years ago
Interventions
QS21biological
sialyl Lewisª-keyhole limpet hemocyanin conjugate vaccinebiological
immunoenzyme techniqueother
immunologic techniqueother
laboratory biomarker analysisother